Reference : Synovium angiogenesis in osteoarthritis: a new therapy target for chondroitin sulfate
Scientific congresses and symposiums : Poster
Human health sciences : Rheumatology
http://hdl.handle.net/2268/86636
Synovium angiogenesis in osteoarthritis: a new therapy target for chondroitin sulfate
English
Mathy, Marianne [Université de Liège - ULg > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.) >]
Lambert, Cécile mailto [Université de Liège - ULg > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.) >]
Dubuc, Jean Emile mailto [Université Catholique de Louvain - UCL > Cliniques Universitaires St Luc > > >]
Montell, E. mailto [BioIberica SA, Barcelona, Spain > > > >]
Vergés, Jose mailto [BioIberica SA, Barcelona, Spain > > > >]
Henrotin, Yves mailto [Université de Liège - ULg > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.) >]
Sep-2010
Yes
No
2010 World Congress on Osteoarthritis
September 23-26, 2010
Bruxelles
Belgium
[en] osteoarthritis ; angiogenesis ; chondroitin sulfate
[en] Osteoarthritis (OA) is an important cause of pain and disability in the ageing population. Angiogenesis and inflammation are closely integrated process in OA and may contribute to its pathogenesis, as well as, affect disease progression and pain. Chondroitin sulfate (CS) is a symptomatic slow acting drug for OA and there is strong evidence suggesting that CS may also be a structure disease modifying osteoarthritis drug. The mechanisms underlying these effects remain poorly understood. This work aimed to demonstrate the relation between inflammation and angiogenesis of synovium and to study the effect of CS on synovium angiogenesis.
http://hdl.handle.net/2268/86636

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
poster ORASI2010 MM.pptxPublisher postprint176.45 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.